EMEA-000309-PIP04-17-M03
Key facts
| Invented name |
RoActemra
|
| Active substance |
tocilizumab
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0303/2021
|
| PIP number |
EMEA-000309-PIP04-17-M03
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of cytokine release syndrome associated with chimeric antigen receptor (CAR) T cell therapy or T-cell-engaging bispecific antibody therapy
|
| Route(s) of administration |
|
| Contact for public enquiries |
Roche Registration GmbH
Tel. +41 616879411 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|